title: [Hepatic involvement in patients with non-Hodgkins lymphoma].
abstract: Non-Hodgkins lymphoma (NHL) represent the most frequent hematological malignancy with frequent extranodal involvement. We have identified 79 pts (4.6%) out of 1,712 patients with NHL, who were diagnosed in our center between 1999-2010. Five cases were primary extranodal lymphomas and we have observed one primary hepatic lymphoma (0.015%). The most frequent (61.3%) NHL subtype in our cohort was diffuse large B-cell lymphoma. B-NHL formed 92.4% of all lymphomas. We have observed high number of HBsAg positive patients (10%). The whole group have poor prognostic features with high number of patients (85%) with intermediate-high and high risk according to international prognostic index. The patients were treated with chemotherapy in 95%, B-NHL patients recieved immunochemotherapy with rituximab in 77%. The median progression free survival, resp. overall survival 4.6, resp. 8.4 years in the whole group and 1.4, resp. 8.4 years in diffuse large B-cell lymphoma were observed with median follow-up 4.5 years. The outcome of T-NHL patients was significantly worse with overall survival median 1.2 vs 8.4 years (p < 0.033). The patients with B-NHL treated by immunochemoterapy with rituximab had significant death risk reduction (HR 0.44, p = 0.03) compared to the patients treated with chemotherapy.
authors.affiliation: I. interní klinika 1. lékařské fakulty UK a VFVN Praha.trneny@cesnet.cz
authors.forename: M
authors.initials: M
authors.lastname: Trněný
authors.forename: J
authors.initials: J
authors.lastname: Sálková
authors.forename: J
authors.initials: J
authors.lastname: Dlouhá
authors.forename: J
authors.initials: J
authors.lastname: Stříteský
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D015331:Cohort Studies; D018572:Disease-Free Survival; D006514:Hepatitis B Surface Antigens / Q000276:immunology; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy* / Q000276:immunology; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy / Q000276:immunology; D016399:Lymphoma, T-Cell / Q000188:drug therapy* / Q000276:immunology; D011379:Prognosis; D000069283:Rituximab
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D006514:Hepatitis B Surface Antigens; D000069283:Rituximab